证券研究报告·公司点评报告 2026 年 3 月 4 日 江海证券研究发展部 医药行业研究组 执业证书编号：S1410524050001 | 投资评级： | 买入（维持） | | --- | --- | | 当前价格: | 34.72元 | | 市场数据 | | | | | | --- | --- | --- | --- | --- | | 总股本(百万股) | | 117.32 | | | | A 股股本(百万股) | | 117.32 | | | | B/H 股股本(百万股) | | -/- | | | | A 股流通比例(%) | | 88.44 | | | | 12 个月最高/最低(元) | | 66.66/33.65 | | | | 第一大股东 | | 李永安 | | | | 第一大股东持股比例(%) | | 10.38 | | | | 上证综指/沪深 300 | | | | 4122.68/4655.90 | | 数据来源：聚源 注：2026 | 3 | 3 日数据 | 年 | 月 | 近十二个月股价表现 % 1 个月 3 个月 12 个月 相对收益 9.40 -4.04 45.06 绝对收益 0 ...

Investment Rating - The report assigns a rating of "Outperform" to the company, indicating a positive outlook for its stock performance relative to the market [2][8]. Core Insights - The company reported a revenue of 1.058 billion yuan for 2025, reflecting a year-on-year growth of 21.8%, and a net profit attributable to shareholders of 237 million yuan, up 33.9% [5][8]. - In Q4 2025, the company achieved a revenue of 262 million yuan, a 21.5% increase year-on-year, and a net profit of 78 million yuan, which is a 26.4% increase [5][8]. - The company is expanding its generic drug product line while simultaneously advancing its new drug development, with a focus on cost reduction and efficiency improvements [5][8]. Financial Data and Profit Forecast - The company’s total revenue is projected to be 1.171 billion yuan in 2026, with a slight decrease to 1.110 billion yuan in 2027 [7]. - The net profit forecast for 2025 is 237 million yuan, followed by 174 million yuan in 2026 and 140 million yuan in 2027, indicating a decline in profitability in the following years [7][9]. - The company’s gross margin is expected to decrease from 83.4% in 2025 to 71.6% in 2027, reflecting potential pricing pressures from market competition [7]. Generic Drug Business - The sales of core products such as "复瑞彤" and "波开清" are steadily increasing, driving growth for the company [8]. - The company is proactively expanding its portfolio of generic drugs, with eight new drug registration approvals obtained in 2025 [8]. Innovative Drug Business - The company is advancing its pipeline of innovative drugs, with the DYX116 project progressing as expected, having completed Phase I clinical trials [8]. - The market for GLP-1 drugs in China is projected to reach 609 billion yuan by 2030, indicating significant growth potential for the company’s innovative drug offerings [8].

Core Viewpoint - The company reported a revenue of 1.058 billion yuan for the fiscal year 2025, representing a year-on-year growth of 21.80%, and a net profit of 237 million yuan, reflecting a year-on-year increase of 33.87% [1] Group 1: Revenue Growth - The primary reason for the growth in operating performance is the company's commitment to a marketing-first business philosophy, which has strengthened the sales foundation and advanced market expansion [1] - The sales volume of key products such as "Furuitong" and "Bokaiqing" has steadily increased, laying a solid foundation for revenue growth [1] - The sales scale of products like Canagliflozin tablets, Empagliflozin tablets, and Metformin Empagliflozin tablets (III) has grown rapidly, further driving the steady improvement in operating performance [1] Group 2: New Product Launches - The launch and sales of newly approved products such as Ezetimibe tablets and Febuxostat tablets have contributed to the revenue increase [1] - Products like Linagliptin tablets (5mg), Sitagliptin Metformin tablets (II) (50mg/850mg), and Saxagliptin tablets (100mg) have been included in the tenth batch of centralized drug procurement, leading to rapid sales growth starting from March 2025 [1] Group 3: Operational Efficiency - The company has continuously strengthened internal operational management, optimized personnel structure, and implemented strict cost control measures to enhance overall profitability and operational quality [1]

Investment Rating - The report maintains a "Buy" rating for the company [4]. Core Views - The company's H1 2025 revenue reached 524 million yuan, a year-on-year increase of 21.3%, and net profit attributable to shareholders was 98 million yuan, up 21.9% [4]. - The company is progressing well in innovative drug development, with multiple catalysts expected within the year [4]. - The report anticipates stable profitability, with an expected increase in R&D investment in H2 2025, while maintaining controllable expense ratios [7]. Financial Summary - Total revenue projections for 2025 are estimated at 1,065 million yuan, with a year-on-year growth rate of 22.6% [6]. - The net profit for 2025 is projected to be 192 million yuan, reflecting an 8.8% year-on-year growth [6]. - The gross margin for H1 2025 was 83.8%, slightly down by 0.8 percentage points year-on-year [7]. Business Segments - The generic drug business showed revenue growth alongside structural optimization, with diabetes and hypertension drugs accounting for 98.6% of revenue in H1 2025 [7]. - The innovative drug segment is advancing, with the DYX116 project in Phase I clinical trials and DYX216 expected to submit an IND application by the end of 2025 [7]. - The company aims to obtain approximately seven new drug approvals annually from 2025 to 2027 [7].

Investment Rating - The investment rating for the company is "Outperform" (maintained) [2][4]. Core Views - The company has received approval for the innovative drug DYX116 for weight loss indications, accelerating its pipeline, with a projected net profit increase of 22% in H1 2025 [2][4]. - The company reported H1 2025 revenue of 525 million yuan, a year-on-year increase of 21.29%, and a net profit of approximately 97.8 million yuan, up 21.94% year-on-year [4]. - The sales volume of diabetes and hypertension products has steadily increased, with significant contributions from key products, and the company is set to benefit from the tenth batch of centralized procurement starting in March 2025 [5][6]. Financial Summary - Revenue projections for 2025-2027 have been revised upwards, with expected net profits of 194 million yuan, 214 million yuan, and 244 million yuan respectively, translating to EPS of 1.65, 1.82, and 2.08 yuan per share [4][8]. - The company’s gross margin is expected to remain strong, with estimates of 83.8% in 2025, and net profit margin projected at 19.1% [8][11]. - The company’s total market capitalization is approximately 4.927 billion yuan, with a current share price of 42.00 yuan [2].